Tirzepatide
Contact Us →Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). It has attracted growing interest in research focused on metabolic health, weight management, and glucose homeostasis.
Studies have shown that Tirzepatide activates GIP and GLP-1 signaling pathways, leading to enhanced insulin secretion, improved appetite suppression, delayed gastric emptying, and superior glycemic control. The dual agonism provides complementary metabolic benefits beyond GLP-1 monoagonists. It may also play a role in hepatic steatosis reduction, cardiovascular risk improvement, and sustained body weight reduction.
Key Research Areas:
-
Dual GIP/GLP-1 receptor agonism and metabolic regulation
-
Body weight reduction and obesity treatment
-
Glucose homeostasis and type 2 diabetes management
-
Hepatic fat resolution and NAFLD/NASH research
-
Appetite suppression and energy balance modulation
